Quarterly Result13 May 2026, 02:02 pm
Suven Life Sciences: FY26 Net Loss ₹5,486.28 Lakhs
AI Summary
Suven Life Sciences Ltd's Board Meeting on May 13, 2026, approved audited financial results for the year ended March 31, 2026, reporting a net loss of ₹5,486.28 lakhs. The board also approved the notice for the 37th Annual General Meeting scheduled for August 25, 2026, via video conferencing. Additionally, the board noted the acceptance of waiver of fines by BSE and advised management to ensure strict compliance with SEBI regulations.
Key Highlights
- Audited financial results for FY26 show a net loss of ₹5,486.28 lakhs.
- 37th Annual General Meeting scheduled for August 25, 2026, via video conferencing.
- BSE waived fines for non-compliance with Regulation 19 of SEBI (LODR) Regulations, 2015.
- NSE waiver application outcome is still awaited.
- Board advises greater diligence in SEBI (LODR) compliance and seeking professional advice.
Price Impact
More from SUVEN